August 8, 2025
Assembly Bio Reports Phase 1b Success in Herpes; Gilead Increases Stake with 2.3M Shares
Assembly Bio; Phase 1b trial; ABI-5366; herpes simplex virus (HSV-2); viral shedding reduction; genital lesion reduction; safety profile; Gilead Sciences; collaboration; stock purchase
AbbVie and Genmab Move to Expand Use of T Cell Engager Epkinly Following Strong Phase III Results
Epkinly; epcoritamab; AbbVie; Genmab; follicular lymphoma; T cell engager; bispecific antibody; Phase III trial; FDA approval; label expansion; Rituximab; Lenalidomide
Two Courts Reject Challenges to Inflation Reduction Act, Marking Major Win for Government
Inflation Reduction Act; IRA; Medicare Drug Negotiation Program; AstraZeneca; federal courts; constitutional challenge; administrative law; Third Circuit Court; CMS; Medicare
Bicycle Therapeutics Lays Off 25% of Workforce After Genentech Collaboration Ends
Bicycle Therapeutics; layoffs; Genentech; R&D partnership; biotech; cost reduction; workforce reduction; strategic realignment
CDC Launches ‘Free Mind’ Campaign Targeting Teen Substance Use and Mental Health
CDC; Free Mind campaign; youth mental health; substance use; drug overdose; fentanyl; teen suicide; coping strategies
Agentic AI is Here: Real-World Applications in Life Sciences & Healthcare (2025 Update)
Agentic AI; life sciences; healthcare; R&D; pharma; personalized medicine; pharmacovigilance; commercialization; automation; data analysis
Novo Nordisk Maintains Edge in Obesity Pill Race as Lilly’s Pill Shows Modest Results
Novo Nordisk; Eli Lilly; obesity pill; oral semaglutide; orforglipron; weight loss drugs; Wegovy; Zepbound; GLP-1; market competition
Lilly’s Q2 2025 Beat-and-Raise Overshadowed by Orforglipron Data
Eli Lilly; Q2 2025 earnings; orforglipron; oral GLP-1; weight loss; obesity franchise; regulatory submission; analyst expectations
FDA Launches PreCheck Program to Accelerate Domestic Drug Manufacturing
FDA PreCheck; domestic drug manufacturing; pharmaceutical supply chain; API; regulatory streamlining; facility construction; national security; Trump administration